title: [Pharmacological properties of paliperidone ER (INVEGA(®)) and results of its clinical studies].
authors.forename: Kenji
authors.initials: K
authors.lastname: Nagino
authors.forename: Tadaishi
authors.initials: T
authors.lastname: Koh
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Harada
mesh_terms: D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D002375:Catalepsy / Q000139:chemically induced; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D004311:Double-Blind Method; D006801:Humans; D007555:Isoxazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D000068882:Paliperidone Palmitate; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D044402:Receptor, Serotonin, 5-HT2A / Q000378:metabolism; D017448:Receptors, Dopamine D2 / Q000378:metabolism; D012559:Schizophrenia / Q000188:drug therapy*; D055502:Secondary Prevention
chemical_list: D007555:Isoxazoles; D011743:Pyrimidines; D044402:Receptor, Serotonin, 5-HT2A; D017448:Receptors, Dopamine D2; D000068882:Paliperidone Palmitate